Video

Q&A With Danny McBryan From Boehringer Ingelheim: Patients With IPF Have First Signs of Hope With Approval of New Medication

Author(s):

In the world of pulmonary conditions idiopathic pulmonary fibrosis is among the rarest, and up until recently there were no treatments available to help these patients. With the approval of OFEV there is now something that can be done while more research is conducted.

In the world of pulmonary conditions idiopathic pulmonary fibrosis is among the rarest, and up until recently there were no treatments available to help these patients. With the approval of OFEV there is now something that can be done while more research is conducted.

Danny McBryan, MD, who serves as vice president Clinical Development and Medical Affairs, Respiratory, for Boehringer Ingelheim Pharmaceuticals, called the approval of OFEV a "great success story," while presenting data on the medication during the annual CHEST conference being held this year in Montreal.

For conditions like asthma and COPD the market is flooded with medications and treatment options meant to help patients manage their symptoms. For patients with IPF having even one viable option can make a world of difference.

Related Videos
Advocating for Race-Neutral Approach to Pulmonary Function Testing with Meredith McCormack, MD, and Loretta Que, MD
Duloxetine for Patients with COPD Suffering from Comorbid Depression
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
© 2025 MJH Life Sciences

All rights reserved.